CANF | tickerfilter.com

Fundamental analysis

22%

Profitability 25%

Dept financing 12%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-5.35%

1 Month

10.58%

3 Months

1,306.73%

6 Months

601.86%

1 Year

187.50%

2 Year

115.96%

Key data

Stock price

$4.60

P/E Ratio

0.00

DAY RANGE

$4.50 - $5.35

EPS

-$22.99

52 WEEK RANGE

$0.17 - $10.40

52 WEEK CHANGE

$191.14

MARKET CAP

59.821 M

YIELD

N/A

SHARES OUTSTANDING

1.541 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

1.20

PUBLIC FLOAT

AVERAGE 10 VOLUME

$4,975,927

AVERAGE 30 VOLUME

$1,935,929

Company detail

CEO: Pnina Fishman
Region: US
Website: canfite.com
Employees: 8
IPO year: 2012

Issue type: American Depository Receipt (ADR’s)
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Can-Fite BioPharma Ltd. develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the. treatment of psoriasis; and Phase II clinical trials for COVID-19. It also develops Namodenoson that is in Phase III. trial for. hepatocellular carcinoma, as well as in Phase IIb trial for treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial.

CANF - Can-Fite BioPharma Ltd.